In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Status: Completed

Conditions: Postpartum Hemorrhage

Treatments: Drug: Oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT01865669

13-04

Details and patient eligibility

About

Women with advanced maternal age and morbid obesity, have a higher incidence of labor induction/ augmentation and cesarean section (CS), and are at a greater risk for postpartum hemorrhage (PPH). Oxytocin is the first line drug in the treatment of PPH, however, oxytocin receptor (OTR) desensitization has been recognized in the context of prolonged labors secondary to either endogenous or exogenous oxytocin exposure. It is unknown if oxytocin desensitization specifically affects contractility in women with advanced maternal age and morbid obesity when compared to younger or normal weight populations. Further it is not known if the higher incidence of PPH seen in these women is due to poor uterine contractility and/or poor response to oxytocin.

The investigators hypothesize that women with advanced maternal age and morbid obesity will exhibit poor myometrial contractility as compared to women that are younger and of normal body habitus, in both oxytocin pre-treated and untreated myometrium.

Full description

In view of the growing concern over the rising incidence of later maternal age and morbid obesity in the obstetric population, scientific evidence on pregnancy outcomes in these patients is timely and important. The investigators' previously validated in-vitro model provides a solid foundation for the study of myometrial contractility under controlled conditions, without any confounders that could be encountered in clinical settings. It is also likely to provide in-depth understanding of the parameters that the investigators feel are responsible for higher incidence of PPH in these patients. The investigators' study will form a basis for future modifications in oxytocin augmentation regimens and pharmacotherapy for control of PPH in these patient populations.

Enrollment: 44 patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients who give written informed consent
• patients requiring elective primary or 1st repeat Cesarean section
• patients with gestational age 37-41 weeks
• non-labouring patients, not exposed to exogenous oxytocin
• Cesarean section under spinal anesthetic
• patients <30 years of age with a normal pre-pregnancy BMI (20 and 24.9 kg/m2)
• patients ≥40 years of age with a normal pre-pregnancy BMI
• patients with a BMI≥40 kg/m2 and age <30 years

Exclusion criteria

• patients who refuse to give written informed consent
• patients who require general anesthesia
• patients who have had more than one previous uterine surgery/CS
• patients with placental abnormalities (abruption, accreta, percreta)
• patients with bleeding disorders
• presence of any other risk factors for PPH

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

44 participants in 2 patient groups

Control

No Intervention group

Description:

A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.

Oxytocin

Experimental group

Description:

Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.

Treatment:

Drug: Oxytocin